Establishment of a NOD/SCID mouse model with human immune reconstitution bearing human triple-negative breast cancer
10.3969/j.issn.1673-4254.2015.01.11
- VernacularTitle:人源性荷三阴乳腺癌NOD/SCID小鼠模型建立及其免疫应答
- Author:
Qiaochu ZHANG
1
;
Xi LI
;
Ruilei LIU
;
Hua JIANG
;
Zenan HUANG
;
Yu LIU
;
Mi TANG
;
Yong HUANG
Author Information
1. 中山大学附属第三医院甲状腺乳腺外科
- Keywords:
immune reconstitution;
immunological therapy;
NOD/SCID mice;
triple-negative breast cancer
- From:
Journal of Southern Medical University
2015;(1):56-61
- CountryChina
- Language:Chinese
-
Abstract:
Objective To establish a NOD/SCID mouse model with human immune reconstitution and observe its immune response to human triple-negative breast cancer xenograft. Methods Twenty-four NOD/SCID mice without immune leakage were subjected to cyclophosphamide (CTX) treatment 3 days prior to immune reconstitution with human peripheral blood mononuclear cell (PBMC) injection and subcutaneous transplantation of human triple-negative breast cancer MDA-MB-231 cells, CTX treatment and PBMC injection without tumor cell transplantation, MDA-MB-231 cell transplantation only, or no treatments. The tumor growth and immune responses of the mice were observed at regular intervals. Results Compared with the tumor-bearing mice, the tumor-bearing mice with immune reconstitution showed prolonged incubation period of tumor formation, slower tumor growth rate and increased survival rate. Human IgG and CD3+T cells were detected in the peripheral blood of the mice 1 week after human PBMC injection. The percentage of CD3+T cells in the spleen cells was 55.3%at 9 weeks in tumor-bearing mice with immune reconstitution and 52.7% in tumor-bearing mice without immune reconstitution. The spleen index of the tumor-bearing mice with immune reconstitution was much higher than that in mice with only immune reconstitution and the control mice (9.64 vs 3.82±0.31 and 1.51±0.14 mg/g). Conclusion A stable NOD/SCID mouse model with immune reconstitution has been established successfully, which shows immune responses to triple-negative breast cancer xenografts and allows studies of immunological therapy study of triple-negative breast cancer.
